You can add Maine to the growing list of states that have passed a law seeking more transparency about prescription drug pricing.
However, unlike a few states that quickly required drug makers to provide cost and pricing information about their medicines – California, Vermont, Nevada, and Oregon — Maine is taking a two-step approach.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
This line struck me – “passing legislation to lower drug costs should be a “top priority” for President Trump, who is expected to deliver a speech about the issue.”
I thought the President’s objection to the last administration was ‘all talk and no action’ – the tradition continues, it would seem. (And wasn’t said speech due last week?)
please send me the information